Military Researchers to Conduct Clinical Study of a "Skin Substitute" Using a Patient's Own Cells to Treat Complex Burns and Soft Tissue Injuries

Oct 13, 2015, 12:21 ET from FN Media Group, LLC

CORAL SPRINGS, Florida, October 13, 2015 /PRNewswire/ --

Cooperative research and development efforts with the military, universities and the biotech industry can potentially lead to advancements in the treatment of severe wounds.  Biotech companies with recent developments, partnerships and advancements in focus are Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Array BioPharma, Inc. (NASDAQ: ARRY), Avanex Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX)

According to a Military Times article published on October 11, 2015 entitled "Bio-Engineering Skin to Treat Severe Burns", military researchers are putting the final touches on a study of a "skin substitute" grown from a patient's own cells to treat complex burns and soft tissue injuries.  

The new research study underway at the U.S. Army Institute of Surgical Research in San Antonio holds promise for treating burn patients, including those with severe, life-threatening wounds. The treatment, called "engineered skin substitute," or ESS, combines tissue cultivated from a patient's skin along with collagen-producing cells to replace the two top components of skin, the epidermis and dermis. Using the patient's cells avoids the need for foreign substitutes and lowers the chances of infection, which in turn avoids the need for immunosuppressants and reduces the number of surgeries required.

ESS is being developed by California-based biotechnology firm Amarantus BioScience (OTCQX: AMBS) and researchers from USAISR and Rutgers University.

Skin autografts - using an individual's own cells or skin to replace damaged tissue - have been around for years, but the technology for rapidly growing replacement skin to use in large-scale burn replacement has lagged.  Moreover, many current products replace either one layer of skin or the other, but not the top two layers together. A comprehensive substitute has long been the "Holy Grail of burn surgery," said Army Col. Booker King, director of the USAISR's Burn Center. "To be able to treat a patient who has burn injuries, you have to remove the deeply burned tissue [and cover it]. Skin is complex … a burn will not heal on its own. You have to have grafting," King said.

Read the full Military Times Article at

In other biopharmaceutical news and developments of interest:  Array BioPharma, Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, recently presented clinical trial results from its wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, at the European Society of Medical Oncology's (ESMO) annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

Anavex Life Sciences Corp. (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, announced on October 7th the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015.  The late-breaking oral session will be presented by the trial's Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.

Juno Therapeutics, Inc. (NASDAQ: JUNO) a company building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer, was highlighted on October 6, 2015 in a research update from FBR& Co., a full an investment bank headquartered in Arlington, Va. FBR has an outperform rating on Juno with a price target of $73 per share.  In an excerpt from the update the FBR analyst stated, "We believe the company is different from competitors in its selection and activation of the cells, and this differentiation can be in part credited to its proprietary reagents and the attention it pays to process development. We believe investors are focused on leukemia and solid tumors and may be unaware of the advancements that Juno is making in lymphoma. We anticipate that this indication will start to draw more investor interest and that the company is already highlighting it more in presentations. The company's pipeline is deep with 10 candidates potentially in clinical trials using either CAR or TCR by early 2016."

Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX) a company developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development, announced on October 12 2015 its offer to acquire EXINI Diagnostics AB (publ), a leader in the development software solutions for medical decision support based on advanced image analysis, through a public offer to the shareholders of EXINI (the "Offer"). EXINI is headquartered in Lund, Sweden, and is listed on Nasdaq First North, Stockholm. The acquisition of EXINI complements Progenics's strategy to support its imaging and therapeutic agents with sophisticated software and other technologies that help physicians and patients visualize, understand, target and treat cancer. is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at  Follow us on Facebook: and Twitter: 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:
U.S. Phone:  +1(954)345-0611

SOURCE FN Media Group, LLC